Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ardea Biosciences provides update on lesinurad development

Sep. 9, 2011

Takeda advances DPP IV inhibitor into Japanese phase III trials in type 2 diabetes

Sep. 8, 2011

TWi Biotechnology completes enrollment in phase IIb AC-201 trial

Sep. 8, 2011

Long-term therapy with cysteamine eye drops assessed in subjects with cystinosis

Sep. 8, 2011

University of Pennsylvania awards grant to OPKO for MPS I therapy

Sep. 7, 2011

Shionogi & Co. claims new neuropeptide Y5 receptor antagonists

Sep. 6, 2011

New progesterone receptor antagonists claimed

Sep. 6, 2011

Daiichi Sankyo identifies new pyrrolobenzoxazepine derivatives

Sep. 6, 2011

SkyePharma completes proof-of-concept study of SKP-1052

Sep. 5, 2011

Bayer Schering Pharma discloses novel progesterone receptor antagonists

Sep. 5, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...